Cisen Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	853.84	1,212	1,161	983.39	997.95	938.98
Short-Term Investments	-	461.47	357.58	154.11	236.27	-
Trading Asset Securities	2,349	1,730	1,275	1,638	1,550	1,485
Cash & Short-Term Investments	3,203	3,403	2,794	2,775	2,784	2,424
Cash Growth	16.27%	21.83%	0.66%	-0.32%	14.87%	-4.46%
Accounts Receivable	970.61	1,041	1,257	1,363	1,272	1,048
Other Receivables	7.78	0.84	0.75	4.24	9.25	11.35
Receivables	978.4	1,042	1,257	1,367	1,281	1,060
Inventory	616.29	623.69	810.43	708.22	580.43	594.65
Other Current Assets	618.09	140.94	100.34	119.41	99.63	66.45
Total Current Assets	5,416	5,210	4,962	4,970	4,745	4,145
Property, Plant & Equipment	1,627	1,675	1,546	1,390	1,489	1,591
Long-Term Investments	5.43	390.03	665.08	602.27	265.08	308.01
Other Intangible Assets	194.15	196.29	203.97	211.6	213.03	210.82
Long-Term Deferred Tax Assets	70.18	78.34	77.41	79.83	86.72	81.65
Long-Term Deferred Charges	-0.2	-	0.47	1.91	3.86	2.05
Other Long-Term Assets	343.37	47.89	99.14	81.94	12.87	25.54
Total Assets	7,656	7,597	7,554	7,338	6,815	6,364
Accounts Payable	578.77	620.31	549.49	468.01	459.71	434.97
Accrued Expenses	77.06	233.37	329.92	139.77	259.48	214.52
Short-Term Debt	13.24	12.08	71.98	34.8	57.79	130
Current Portion of Long-Term Debt	2.42	-	32.63	-	-	-
Current Portion of Leases	-	2.04	2.64	3.34	0.3	2.72
Current Income Taxes Payable	50.25	6.28	11.71	34.67	5.61	1.18
Current Unearned Revenue	70.27	64.35	78.11	100.16	118.78	70.05
Other Current Liabilities	372.21	285.34	412.36	589.17	380.24	365.5
Total Current Liabilities	1,164	1,224	1,489	1,370	1,282	1,219
Long-Term Debt	23.69	25.79	7.7	128.5	100	-
Long-Term Leases	2.68	3.61	0.89	4.03	0.51	10.91
Long-Term Unearned Revenue	91.67	94.04	57.17	56.25	65.36	74.43
Long-Term Deferred Tax Liabilities	10.9	19.54	12.28	12.68	11.46	3.87
Total Liabilities	1,293	1,367	1,567	1,571	1,459	1,308
Common Stock	452.75	452.75	452.75	452.78	453.31	453.33
Additional Paid-In Capital	1,934	1,934	1,929	1,919	1,913	1,863
Retained Earnings	3,937	3,807	3,570	3,358	2,989	2,774
Treasury Stock	-	-	-	-0.08	-19.77	-32.74
Comprehensive Income & Other	-2.63	-2.65	-2.71	-2.69	-2.93	-3.07
Total Common Equity	6,322	6,191	5,950	5,727	5,332	5,055
Minority Interest	40.89	39.52	37.39	39.1	23.64	0.75
Shareholders' Equity	6,363	6,231	5,987	5,766	5,356	5,056
Total Liabilities & Equity	7,656	7,597	7,554	7,338	6,815	6,364
Total Debt	42.03	43.53	115.83	170.67	158.61	143.63
Net Cash (Debt)	3,161	3,360	2,678	2,604	2,625	2,280
Net Cash Growth	15.78%	25.47%	2.81%	-0.79%	15.15%	3.32%
Net Cash Per Share	6.97	7.42	5.89	5.75	5.78	5.05
Filing Date Shares Outstanding	450.85	452.75	452.75	452.76	451.36	449.83
Total Common Shares Outstanding	450.85	452.75	452.75	452.76	451.34	449.83
Working Capital	4,252	3,986	3,473	3,600	3,463	2,926
Book Value Per Share	14.02	13.67	13.14	12.65	11.81	11.24
Tangible Book Value	6,128	5,995	5,746	5,516	5,119	4,844
Tangible Book Value Per Share	13.59	13.24	12.69	12.18	11.34	10.77
Buildings	-	1,412	1,277	1,275	1,188	1,191
Machinery	-	2,469	2,109	2,092	1,903	1,797
Construction In Progress	-	163.6	405.8	66.68	207.17	199.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.